News
-
-
-
-
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments publishes Quarterly Report as at 31 December 2024 with key figures for the first nine months of the 2024/2025 financial year
HBM Healthcare Investments reports a profit of CHF 66 million in the first nine months of the 2024/2025 financial year, driven by private portfolio companies. NAV up 4.3%, share price down 5.2% -
COMMUNIQUÉ DE PRESSE
Schindler Holding Ltd.: Changes to the Board of Directors
Schindler Holding Ltd. announces changes to the Board of Directors and CEO appointment. Josef Ming proposed for election as Chairman. Paolo Compagna to assume CEO role on February 1, 2025. Silvio Napoli not to stand for re-election -
COMMUNIQUÉ DE PRESSE
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Formycon receives EU approval for biosimilar FYB203 (aflibercept) to Eylea®, brands AHZANTIVE® and Baiama® for nAMD and retinal diseases. Teva to market AHZANTIVE® in Europe -
-
-
-
COMMUNIQUÉ DE PRESSE
Amarc Announces January Conference Participation
Amarc Resources announces participation in three upcoming conferences in Vancouver, BC, presenting updates on copper-gold districts and new AuRORA discovery in JOY District. Executive team to lead presentations and showcase drill core at AME Roundup
